Last checked at 7 Sep 2020 13:30
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Exercise of Warrant
London, UK 7 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces it has received notification for the exercise of a warrant over 215,384 ordinary shares in the Company at an exercise price of 16.25 pence per share providing the Company with proceeds of £35,000 ("Warrant Exercise").
Application will be made to the London Stock Exchange to admit the 215,384 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 11 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 57,319,423 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
|
| ||||||||
|
| ||||||||
|
|